Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Director departure

Nexvet Biopharma plc (NVET) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/13/2018 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
08/10/2017 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
08/08/2017 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/02/2017 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/02/2017 4 McCracken Joseph S (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 16,400 shares @ $6.72, valued at $110.2k
08/02/2017 4 Lismore Damian T. (CFO) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 67,750 shares @ $6.72, valued at $455.3k
Disposed/sold 21,239 shares @ $6.72, valued at $142.7k
Disposed/sold 18,724 shares @ $6.72, valued at $125.8k
Disposed/sold 27,500 options to buy @ $0.125, valued at $3.4k
Disposed/sold 48,750 options to buy @ $0.125, valued at $6.1k
Disposed/sold 100,000 options to buy @ $15, valued at $1.5M
08/02/2017 4 Kilty Cormac G (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 10,800 shares @ $6.72, valued at $72.6k
Disposed/sold 144,364 shares @ $6.72, valued at $970.1k
08/02/2017 4 HORN JURGEN (Chief Product Development Ofcr) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 15,750 shares @ $6.72, valued at $105.8k
Disposed/sold 60,000 options to buy @ $5.1, valued at $306k
Disposed/sold 47,250 options to buy @ $0.125, valued at $5.9k
08/02/2017 4 Heffernan Mark (CEO) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 109,810 shares @ $6.72, valued at $737.9k
Disposed/sold 243,587 shares @ $6.72, valued at $1.6M
Disposed/sold 50,000 options to buy @ $0.125, valued at $6.3k
Disposed/sold 106,929 options to buy @ $0.125, valued at $13.4k
Disposed/sold 4,833 options to buy @ $0.125, valued at $604.1
Disposed/sold 9,203 options to buy @ $0.125, valued at $1.2k
Disposed/sold 52,040 options to buy @ $6.35, valued at $330.5k
Disposed/sold 100,000 options to buy @ $15, valued at $1.5M
08/02/2017 4 Hanna Ashraf (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 16,020 shares @ $6.72, valued at $107.7k
Disposed/sold 1,500 shares @ $6.72, valued at $10.1k
08/02/2017 4 Gunn George W (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 42,600 shares @ $6.72, valued at $286.3k
Disposed/sold 1,500 options to buy @ $0.125, valued at $187.5
08/02/2017 4 Farrell Geraldine T (VP Operations, General Counsel) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 18,980 shares @ $6.72, valued at $127.5k
Disposed/sold 33,180 shares @ $6.72, valued at $223k
Disposed/sold 30,000 options to buy @ $0.125, valued at $3.8k
Disposed/sold 4,678 options to buy @ $0.125, valued at $584.8
Disposed/sold 20,000 options to buy @ $15, valued at $300k
08/02/2017 4 Brown Christopher Nigel (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 7,200 shares @ $6.72, valued at $48.4k
Disposed/sold 8,800 shares @ $6.72, valued at $59.1k
Disposed/sold 3,600 options to buy @ $0.125, valued at $450
Disposed/sold 7,080 options to buy @ $0.125, valued at $885
08/02/2017 4 PATEL RAJIV A (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Disposed/sold 13,580 shares @ $6.72, valued at $91.3k
Disposed/sold 1,000 options to buy @ $6.595, valued at $6.6k
08/02/2017 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/02/2017 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/31/2017 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/31/2017 RW Form RW - Registration Withdrawal Request:
07/31/2017 8-K Quarterly results
07/31/2017 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
07/10/2017 8-K Form 8-K - Current report:
07/05/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
07/05/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
07/05/2017 4 Kilty Cormac G (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Exercised 3,600 options to buy @ $0.125, valued at $450
07/05/2017 4 HORN JURGEN (Chief Product Development Ofcr) has filed a Form 4 on Nexvet Biopharma plc
Txns: Exercised 15,750 options to buy @ $0.125, valued at $2k
07/05/2017 4 Farrell Geraldine T (VP Operations, General Counsel) has filed a Form 4 on Nexvet Biopharma plc
Txns: Exercised 10,000 options to buy @ $0.125, valued at $1.3k
Exercised 2,340 options to buy @ $0.125, valued at $292.5
Exercised 2,866 options to buy @ $0.125, valued at $358.3
Exercised 6,194 options to buy @ $0.125, valued at $774.3
07/05/2017 4 Brown Christopher Nigel (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Exercised 3,600 options to buy @ $0.125, valued at $450
07/05/2017 4 McCracken Joseph S (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Exercised 500 options to buy @ $0.125, valued at $62.5
Exercised 3,600 options to buy @ $0.125, valued at $450
07/05/2017 4 Hanna Ashraf (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Exercised 500 options to buy @ $0.125, valued at $62.5
Exercised 3,600 options to buy @ $0.125, valued at $450
07/05/2017 4 Gunn George W (Director) has filed a Form 4 on Nexvet Biopharma plc
Txns: Exercised 500 options to buy @ $0.125, valued at $62.5
Exercised 3,600 restricted stock units @ $0.125, valued at $450
07/05/2017 4 Lismore Damian T. (CFO) has filed a Form 4 on Nexvet Biopharma plc
Txns: Exercised 65,000 options to buy @ $0.125, valued at $8.1k
Exercised 16,250 options to buy @ $0.125, valued at $2k
Exercised 4,000 options to buy @ $0.125, valued at $500
Exercised 7,079 options to buy @ $0.125, valued at $884.9
07/05/2017 4 Heffernan Mark (CEO) has filed a Form 4 on Nexvet Biopharma plc
Txns: Exercised 25,000 options to buy @ $0.125, valued at $3.1k
Exercised 35,643 options to buy @ $0.125, valued at $4.5k
07/05/2017 8-K Form 8-K - Current report
07/05/2017 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy